These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 24497296)

  • 41. Clinical and biochemical features of uric acid nephrolithiasis.
    Ito H; Kotake T; Nomura K; Masai M
    Eur Urol; 1995; 27(4):324-8. PubMed ID: 7656911
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Uric acid nephrolithiasis: current concepts and controversies.
    Shekarriz B; Stoller ML
    J Urol; 2002 Oct; 168(4 Pt 1):1307-14. PubMed ID: 12352383
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diagnosis and prevention of uric acid stones].
    Ferrari P; Bonny O
    Ther Umsch; 2004 Sep; 61(9):571-4. PubMed ID: 15493118
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluation of the chemical composition of nephrolithiasis using dual-energy CT in Southern Chinese gout patients.
    Li ZX; Jiao GL; Zhou SM; Cheng ZY; Bashir S; Zhou Y
    BMC Nephrol; 2019 Jul; 20(1):273. PubMed ID: 31324154
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Urinary pH and stone formation.
    Wagner CA; Mohebbi N
    J Nephrol; 2010; 23 Suppl 16():S165-9. PubMed ID: 21170875
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Temporal Changes in Kidney Stone Composition and in Risk Factors Predisposing to Stone Formation.
    Xu LHR; Adams-Huet B; Poindexter JR; Maalouf NM; Moe OW; Sakhaee K
    J Urol; 2017 Jun; 197(6):1465-1471. PubMed ID: 28111301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Metabolic basis for low urine pH in type 2 diabetes.
    Maalouf NM; Cameron MA; Moe OW; Sakhaee K
    Clin J Am Soc Nephrol; 2010 Jul; 5(7):1277-81. PubMed ID: 20413437
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pathophysiology, diagnosis and conservative therapy in calcium kidney calculi].
    Hess B
    Ther Umsch; 2003 Feb; 60(2):79-87. PubMed ID: 12649986
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure.
    Faggiano A; Pivonello R; Melis D; Filippella M; Di Somma C; Petretta M; Lombardi G; Colao A
    J Clin Endocrinol Metab; 2003 May; 88(5):2076-80. PubMed ID: 12727957
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term treatment of calcium nephrolithiasis with potassium citrate.
    Pak CY; Fuller C; Sakhaee K; Preminger GM; Britton F
    J Urol; 1985 Jul; 134(1):11-9. PubMed ID: 3892044
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Metabolic diagnoses of recurrent stone formers: temporal, geographic and gender differences.
    Huynh LM; Dianatnejad S; Tofani S; Carrillo Ceja R; Liang K; Tapiero S; Jiang P; Youssef RF
    Scand J Urol; 2020 Dec; 54(6):456-462. PubMed ID: 33185135
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urinary alkalization for the treatment of uric acid nephrolithiasis.
    Cicerello E; Merlo F; Maccatrozzo L
    Arch Ital Urol Androl; 2010 Sep; 82(3):145-8. PubMed ID: 21121431
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of Urine Findings with Metabolic Syndrome Traits in a Population of Patients with Nephrolithiasis.
    Hood VL; Sternberg KM; de Waal D; Asplin JR; Mulligan C; Callas PW
    Kidney360; 2022 Feb; 3(2):317-324. PubMed ID: 35373120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Uric acid nephrolithiasis].
    Dussol B
    Rev Prat; 2011 Mar; 61(3):389-92. PubMed ID: 21563421
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group.
    Prezioso D; Strazzullo P; Lotti T; Bianchi G; Borghi L; Caione P; Carini M; Caudarella R; Ferraro M; Gambaro G; Gelosa M; Guttilla A; Illiano E; Martino M; Meschi T; Messa P; Miano R; Napodano G; Nouvenne A; Rendina D; Rocco F; Rosa M; Sanseverino R; Salerno A; Spatafora S; Tasca A; Ticinesi A; Travaglini F; Trinchieri A; Vespasiani G; Zattoni F;
    Arch Ital Urol Androl; 2015 Jul; 87(2):105-20. PubMed ID: 26150027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Studies on the pathophysiology of the low urine pH in patients with uric acid stones.
    Kamel KS; Cheema-Dhadli S; Halperin ML
    Kidney Int; 2002 Mar; 61(3):988-94. PubMed ID: 11849453
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic syndrome: a multifaceted risk factor for kidney stones.
    Domingos F; Serra A
    Scand J Urol; 2014 Oct; 48(5):414-9. PubMed ID: 24708398
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 24-h uric acid excretion and the risk of kidney stones.
    Curhan GC; Taylor EN
    Kidney Int; 2008 Feb; 73(4):489-96. PubMed ID: 18059457
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of Two Dietary Supplements for Treatment of Uric Acid Renal Lithiasis: Citrate vs. Citrate + Theobromine.
    Hernandez Y; Costa-Bauza A; Calvó P; Benejam J; Sanchis P; Grases F
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32645831
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acid-base metabolism: implications for kidney stones formation.
    Hess B
    Urol Res; 2006 Apr; 34(2):134-8. PubMed ID: 16411127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.